BioLineRx Ltd. (BLRX) Receives Average Recommendation of “Buy” from Analysts
BioLineRx Ltd. (NASDAQ:BLRX) has been assigned a consensus rating of “Buy” from the seven brokerages that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $2.88.
BLRX has been the subject of several analyst reports. Zacks Investment Research upgraded BioLineRx from a “sell” rating to a “hold” rating in a report on Wednesday, July 26th. Roth Capital initiated coverage on BioLineRx in a report on Thursday, August 3rd. They issued a “buy” rating and a $3.00 price objective for the company. Oppenheimer Holdings, Inc. initiated coverage on BioLineRx in a report on Friday, August 4th. They issued an “outperform” rating and a $3.00 price objective for the company. Maxim Group set a $3.00 price objective on BioLineRx and gave the company a “buy” rating in a report on Tuesday, August 8th. Finally, HC Wainwright set a $4.00 price objective on BioLineRx and gave the company a “buy” rating in a report on Wednesday, August 9th.
An institutional investor recently bought a new position in BioLineRx stock. Renaissance Technologies LLC acquired a new position in shares of BioLineRx Ltd. (NASDAQ:BLRX) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 131,480 shares of the biotechnology company’s stock, valued at approximately $126,000. Renaissance Technologies LLC owned about 0.21% of BioLineRx as of its most recent SEC filing. 32.59% of the stock is owned by hedge funds and other institutional investors.
Shares of BioLineRx (NASDAQ:BLRX) traded up $0.01 during midday trading on Friday, hitting $1.01. The stock had a trading volume of 255,589 shares, compared to its average volume of 282,078. BioLineRx has a 12 month low of $0.80 and a 12 month high of $1.38.
BioLineRx Company Profile
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for BioLineRx Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.